Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) added $0.65 to its price during the regular trading session on Wednesday, reaching $13.40. When it comes to volume, 2.07 million shares of this company’s common stock changed hands. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has experienced a 1-year low price of $4.45 and a 1-year high price of $19.90. This organization’s current debt-to-equity ratio is 0.00, its current ratio is 20.60 and its quick ratio is 20.60 at the time of writing. The company has a beta of 5.07.
B. Riley FBR, Inc. Upgrade shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) to a Buy rating from a Neutral rating in a report posted on Tuesday, April 10th, 2018. At the present, they have a price target for the Biotechnology set at $22. Several additional equities analysts have also published recent reports on IOVA stock. B. Riley FBR, Inc., for example, Reiterated Iovance Biotherapeutics, Inc. to Neutral in a report that was made public on Tuesday, March 13th, 2018. B. Riley FBR, Inc. Downgrade a $18.50 price target on Iovance Biotherapeutics, Inc. in a report from Friday, February 23rd, 2018, while giving the stock to a Neutral rating from a Buy rating. In a report sent out on Thursday, January 25th, 2018, H.C. Wainwright Reiterated the stock rating on Iovance Biotherapeutics, Inc. to a Buy. Lastly, a Buy rating on shares of Iovance Biotherapeutics, Inc. was Reiterated by B. Riley FBR, Inc., which also set a $18 price target on the company’s stock. In total, 0 Wall Street analysts have given this stock a hold rating, with 7 analysts rating it as a strong buy. At the time of writing, this stock has a consensus price target set at $25.33 and average analyst rating set to Strong Buy.
There is a technical analysis indicator called the Relative Strength Index, or RSI, and analysts use it to measure momentum within a range of 0 to 100. When a stock’s RSI falls under 30, it is considered to be oversold. For Iovance Biotherapeutics, Inc., specifically, the RSI metric has reached 39.54. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has lost -22.09% in value over the last three months, and 51.41% over the last six-month period. Over the last full year, the stock price has gained 117.89%.
The measurement of a stock’s predictable daily price range is referred to as volatility – and it’s also the price range within which a day trader does his or her business. Higher volatility translates to higher losses or profits. After recently verifying the number, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) stock has a volatility measurement of 7.88% for the week, with 6.43% volatility as observed from the past 30 days. The public company has 98.85M shares outstanding currently, as well as a market cap of $1.32B. This stock’s distance from its 20-day simple moving average is -11.16%, based on a recent bid, while its distance from the 50-day simple moving average is currently -10.29%. Meanwhile, it has a distance of 13.11% from the 200-day simple moving average. Today, this organization is sitting -32.66% away from its 52-week high price and 201.12% away from its 52-week low price.
More detail-oriented stock traders might be keeping tabs on another metric: the Williams Percent Range or Williams %R. The Williams %R measurement is a widely-used technical indicator founded by Larry Williams to enable the identification of oversold and overbought stock territory. Traders will typically use Williams %R alongside other trend indicators to help locate potential turning points in a stock’s price trajectory. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)’s Williams Percent Range, or 14-day Williams %R, is sitting at 76.00 at the time of writing. Generally speaking, if the indicator rises above -20, the shares may be overbought. On the flip side, if the indicator goes below -80, it may mean that the stock has crossed over into oversold territory.
Investors oftentimes keep their eyes on the latest stock price support and resistance levels. The support is a lower “floor” level where a stock may bounce back after it has dipped. If the share price can penetrate the first support level, investor attention may shift to the second level. The resistance is the contrary of support levels. As a stock grows in value, it may see a dip once it reaches a specific level of resistance. After a recent examination, this company’s shares’ first resistance level is sitting at 13.92. Meanwhile, investors are looking out for the first support level, which is 12.64.